Beeravolu Reddy, MD
Interventional Cardiology · Port Huron, MINPI 1679534135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novartis at 36.2% of the total. Reporting peaked in 2023 at $361 and has fallen 85.6% since, to $52 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 51 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$379
- Philips North America LLC$175
- Abiomed$98
- Boston Scientific$75
- Actelion Pharmaceuticals US, Inc.$67
- Amgen$45
- plus $208 from 9 others
What the payments were for
- Food & beverage$97994%
- Education$676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $379 |
| Philips North America LLC | 9 | $175 |
| Abiomed | 2 | $98 |
| Boston Scientific | 3 | $75 |
| Actelion Pharmaceuticals US, Inc. | 1 | $67 |
| Amgen | 3 | $45 |
| Cardinal Health 200 LLC | 3 | $39 |
| Irhythm Technologies, Inc. | 2 | $32 |
| Baxter Healthcare | 2 | $31 |
| AstraZeneca | 2 | $29 |
| Novo Nordisk | 1 | $24 |
| Boehringer Ingelheim | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
| Abbott | 1 | $11 |
How this compares
$1,046 in reported general payments places this provider in the 10th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 500 | $574,154 |
| XareltoRivaroxaban | 144 | $189,755 |
| JardianceEmpagliflozin | 54 | $87,695 |
| EntrestoSacubitril/Valsartan | 23 | $38,236 |
| Atorvastatin Calcium | 806 | $13,628 |
| Repatha SureclickEvolocumab | 11 | $11,147 |
| Metoprolol Tartrate | 1,085 | $8,981 |
| Metoprolol Succinate | 412 | $7,114 |
| Losartan Potassium | 518 | $7,054 |
| CorlanorIvabradine Hcl | 12 | $7,007 |
| ClopidogrelClopidogrel Bisulfate | 337 | $6,987 |
| Rosuvastatin Calcium | 201 | $4,776 |
| Amlodipine Besylate | 447 | $3,896 |
| Amiodarone Hcl | 124 | $3,463 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 150 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $11 | $189,755144 claims |
| Boehringer IngelheimJardiance | $16 | $87,69554 claims |
| NovartisEntresto | $379 | $38,23623 claims |
| AmgenCorlanor | $45 | $7,00712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Port Huron
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
- Khaldoon AlaswadDetroit$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.